Follow
Yoshiteru Takekita
Yoshiteru Takekita
Kansai Medical University
Verified email at takii.kmu.ac.jp
Title
Cited by
Cited by
Year
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder
M Kato, T Fukuda, A Serretti, M Wakeno, G Okugawa, Y Ikenaga, Y Hosoi, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 (2), 398-404, 2008
1812008
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder
M Kato, T Fukuda, A Serretti, M Wakeno, G Okugawa, Y Ikenaga, Y Hosoi, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 (2), 398-404, 2008
1812008
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese …
M Kato, T Fukuda, M Wakeno, K Fukuda, G Okugawa, Y Ikenaga, ...
Neuropsychobiology 53 (4), 186-195, 2006
1762006
Effect of 5‐HT1A gene polymorphisms on antidepressant response in major depressive disorder
M Kato, T Fukuda, M Wakeno, G Okugawa, Y Takekita, S Watanabe, ...
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 150 …, 2009
1062009
Differences in quantitative EEG between frontotemporal dementia and Alzheimer’s disease as revealed by LORETA
K Nishida, M Yoshimura, T Isotani, T Yoshida, Y Kitaura, A Saito, H Mii, ...
Clinical Neurophysiology 122 (9), 1718-1725, 2011
932011
The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran
M Wakeno, M Kato, G Okugawa, T Fukuda, Y Hosoi, Y Takekita, ...
Journal of clinical psychopharmacology 28 (5), 518-524, 2008
442008
Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials
Y Takekita, T Suwa, N Sunada, H Kawashima, C Fabbri, M Kato, A Tajika, ...
European archives of psychiatry and clinical neuroscience 266, 703-717, 2016
352016
Antidepressant response and intolerance to SSRI is not influenced by G-protein β3 subunit gene C825T polymorphism in Japanese major depressive patients
M Kato, M Wakeno, G Okugawa, T Fukuda, Y Takekita, Y Hosoi, J Azuma, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 (4), 1041-1044, 2008
352008
The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, randomized controlled …
Y Koshikawa, Y Takekita, M Kato, S Sakai, A Onohara, N Sunada, ...
Neuropsychobiology 73 (1), 35-42, 2016
342016
Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis
K Matsui, T Tokumasu, Y Takekita, K Inada, T Kanazawa, T Kishimoto, ...
Schizophrenia research 209, 50-57, 2019
332019
Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects
M Kato, G Okugawa, M Wakeno, Y Takekita, S Nonen, S Tetsuo, ...
European neuropsychopharmacology 19 (10), 718-725, 2009
332009
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
Y Takekita, Y Koshikawa, C Fabbri, S Sakai, N Sunada, A Onohara, ...
BMC psychiatry 16, 1-8, 2016
302016
HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: a meta-analysis
Y Takekita, C Fabbri, M Kato, Y Koshikawa, A Tajika, T Kinoshita, ...
International Journal of Neuropsychopharmacology 19 (5), pyv125, 2016
302016
HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in schizophrenia
Y Takekita, C Fabbri, M Kato, S Nonen, S Sakai, N Sunada, Y Koshikawa, ...
Journal of clinical psychopharmacology 35 (3), 220-227, 2015
282015
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs
M Kato, A Serretti, S Nonen, Y Takekita, M Wakeno, J Azuma, T Kinoshita
Translational psychiatry 5 (2), e513-e513, 2015
242015
Therapeutic response to paroxetine in major depressive disorder predicted by DNA methylation
N Takeuchi, S Nonen, M Kato, M Wakeno, Y Takekita, T Kinoshita, ...
Neuropsychobiology 75 (2), 81-88, 2018
212018
5-HTTLPR rs25531A> G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial
M Kato, S Nonen, J Azuma, A Serretti, S Tetsuo, Y Takekita, T Kinoshita
Journal of clinical psychopharmacology 33 (1), 131-132, 2013
202013
Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT
M Kato, Y Takekita, Y Koshikawa, S Sakai, H Bandou, K Nishida, ...
Journal of psychiatric research 89, 97-104, 2017
182017
Polymorphism of rs3813034 in serotonin transporter gene SLC6A4 is associated with the selective serotonin and serotonin-norepinephrine reuptake inhibitor response in depressive …
S Nonen, M Kato, Y Takekita, M Wakeno, S Sakai, A Serretti, T Kinoshita
Journal of clinical psychopharmacology 36 (1), 27-31, 2016
172016
A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients
Y Takekita, M Kato, M Wakeno, S Sakai, A Suwa, K Nishida, G Okugawa, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 40, 110-114, 2013
152013
The system can't perform the operation now. Try again later.
Articles 1–20